The patent provides the Schisandra Lignin extraction method and Schisandra-based products with market exclusivity for a period of 18 years.
Renhuang Pharmaceuticals chairman and CEO Shaoming Li said the company is pleased to receive the patent on its proprietary Schisandra Lignin Extraction Method, which positively reflects on the company’s research capabilities to develop new medicines.
"We at China Botanic are committed to enhancing our research and development potential and strive towards developing products that benefit our consumers and society,” Li added.
The research studies in China recommend Schisandra as a significant medical and health benefits plant, which help prevent liver damage and treat insomnia and central nervous system depression.
The research also states that Lignin compounds are a good source of anti-oxidants that help fight HIV, cancer and high blood pressure.
The patented Schisandra lignin extraction method allows the company to obtain higher purity of lignin by filtering impurities from the plant, resulting in extract with over 50% lignin.